Related Experiment Video
Updated: Jun 13, 2026
06:12
Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube
Published on: April 28, 2020
Treatment options for hepatic encephalopathy.
1Division of Liver Diseases, Mount Sinai Medical Center, New York, New York 10029, USA. thomas.schiano@mssm.edu
Pharmacotherapy
|April 24, 2010
Summary
Rifaximin is an effective treatment for hepatic encephalopathy, comparable or superior to lactulose. This antibiotic reduces ammonia production, improving patient symptoms and cognitive function.
Area of Science:
- Gastroenterology
- Hepatology
- Pharmacology
Background:
- Hepatic encephalopathy (HE) management lacks formal guidelines.
- Lactulose is the first-line treatment, working by acidifying the gut to reduce ammonia production.
- Systemic antibiotics like neomycin have limitations due to adverse events.
Purpose of the Study:
- To review the efficacy and safety of rifaximin for hepatic encephalopathy.
- To compare rifaximin with lactulose in treating HE.
- To discuss current and emerging treatment protocols for HE.
Main Methods:
- Review of clinical studies comparing rifaximin and lactulose for hepatic encephalopathy.
- Analysis of rifaximin's mechanism of action in reducing ammonia production.
- Examination of safety profiles and dosing strategies for rifaximin in HE.
Main Results:
- Rifaximin effectively improves cognitive, behavioral, and laboratory abnormalities in HE patients.
- Clinical studies show rifaximin to be equal or superior to lactulose in efficacy.
- Rifaximin's favorable safety profile and non-systemic action make it a valuable therapeutic option.
Conclusions:
- Rifaximin is a well-tolerated and effective treatment for overt hepatic encephalopathy.
- It offers an alternative or adjunct to lactulose, with comparable or superior outcomes.
- Ongoing research aims to further define optimal rifaximin dosing and its role in HE management.
Related Concept Videos
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Pharmaceutical Poisoning: Treatment Strategies
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...